- Home
- Publications
- Publication Search
- Publication Details
Title
Identification and Characterization of Novel CFTR Potentiators
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-10-26
DOI
10.3389/fphar.2018.01221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent
- (2018) Steven E. Van der Plas et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mutation-specific downregulation of CFTR2 variants by gating potentiators
- (2017) Radu G Avramescu et al. HUMAN MOLECULAR GENETICS
- A common mechanism for CFTR potentiators
- (2017) Han-I Yeh et al. JOURNAL OF GENERAL PHYSIOLOGY
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
- (2017) Jennifer L. Taylor-Cousar et al. NEW ENGLAND JOURNAL OF MEDICINE
- On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator
- (2016) Ying-Chun Yu et al. JOURNAL OF PHYSIOLOGY-LONDON
- Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines
- (2016) Jinhong Park et al. PLoS One
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) Claire E. Wainwright et al. NEW ENGLAND JOURNAL OF MEDICINE
- The relative frequency of CFTR mutation classes in European patients with cystic fibrosis
- (2014) K. De Boeck et al. Journal of Cystic Fibrosis
- Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator
- (2014) Sabine Hadida et al. JOURNAL OF MEDICINAL CHEMISTRY
- Some gating potentiators, including VX-770, diminish F508-CFTR functional expression
- (2014) G. Veit et al. Science Translational Medicine
- Potentiator ivacaftor abrogates pharmacological correction of F508 CFTR in cystic fibrosis
- (2014) D. M. Cholon et al. Science Translational Medicine
- Repairing mutated proteins – development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator
- (2013) Daniel Merk et al. Expert Opinion on Drug Discovery
- Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle
- (2013) Kang-Yang Jih et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel pharmacological strategies to treat cystic fibrosis
- (2013) John W. Hanrahan et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy
- (2012) Bob Lubamba et al. CLINICAL BIOCHEMISTRY
- Ivacaftor potentiation of multiple CFTR channels with gating mutations
- (2012) Haihui Yu et al. Journal of Cystic Fibrosis
- Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia
- (2012) Guido Veit et al. MOLECULAR BIOLOGY OF THE CELL
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Model of the cAMP activation of chloride transport by CFTR channel and the mechanism of potentiators
- (2009) Oscar Moran JOURNAL OF THEORETICAL BIOLOGY
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now